We recognize that Lu et al. performed an experimental study in which adenoviral VEGF-C was delivered to a transferred lymph node [28]; however, the full version of the paper was not found in English, therefore, not fulfilling the inclusion criteria of this study. Despite these limitations, we feel that our study reports valuable pooled data, particularly pertaining to mechanisms of targeted therapies already proposed in lymphedema surgery, which can guide future studies to advance the field. This evidence concerns the gene VEGFC and lymphedema.